Preliminary considerations on the use of nintedanib (BIBF 1120) in lung cancer patients
LE Raez, ES Santos - Lung Cancer Management, 2014 - Taylor & Francis
Angiogenesis is a crucial mechanism for growth, proliferation and metastasis in many tumor
types including lung cancer [1]. The VEGF ligand plays a key role in regulation, both in …
types including lung cancer [1]. The VEGF ligand plays a key role in regulation, both in …
[HTML][HTML] Anti-Angiogenic Therapy for the Treatment of Lung Cancer
H Chen - 2014 - targetedonc.com
Anti-angiogenic therapy aims to disrupt blood supply to tumors and has proven clinical
benefit in nonsquamous non-small cell lung cancer (NSCLC). Bevacizumab, an anti …
benefit in nonsquamous non-small cell lung cancer (NSCLC). Bevacizumab, an anti …
Current status of targeted therapy in non small cell lung cancer (NSCLC)
DV Parums - Drugs of Today, 2014 - access.portico.org
Tumor tissue biomarkers are the basis for targeted therapy in non-small cell lung cancer
(NSCLC). These biomarkers either reflect the target of the specific drug or some factor that …
(NSCLC). These biomarkers either reflect the target of the specific drug or some factor that …
[引用][C] Taxol, taxoids, and related taxanes
I Ojima, A Kamath, JD Seitz - Natural Products in Medicinal …, 2014 - Wiley Online Library
This chapter contains sections titled: Introduction and Historical Background Mechanism of
Action and Drug Resistance Structure–Activity Relationships (SAR) of Taxol Structural and …
Action and Drug Resistance Structure–Activity Relationships (SAR) of Taxol Structural and …
[引用][C] Angiogenesis inhibition and lung-cancer therapy
The initial report by Judah Folkman1 describing the tumour vasculature as a target for
cancer therapy generated much interest in the use of angiogenesis inhibition for the …
cancer therapy generated much interest in the use of angiogenesis inhibition for the …